TY - JOUR
T1 - Reappraisal of kanamycin usage in neonates
AU - Howard, Jorge B.
AU - McCracken, George H.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1975/6
Y1 - 1975/6
N2 - This study documents an important change in the kanamycin susceptibilities of Escherichia coli strains cultivated from neonates. Whereas some nurseries have in the past experienced resistance rates as high as 70%, recent surveillance of seven North American nurseries demonstrated that 90% or more of E. coli strains are currently susceptible to kanamycin. Pharmacokinetic studies of 65 babies treated with either 7.5 or 10 mg/kg kanamycin doses revealed that peak serum values varied with dosage, birthweight, and chronologic age. Peak serum levels were below the desired therapeutic range in many babies treated with 7.5 mg/kg doses of kanamycin every 12 hours. Concentrations in cerebrospinal fluid specimens from 21 infants were 0.5 to 12 μg/ml after 7.5 mg/kg kanamycin doses. Calculated distribution volumes, plasma clearances, and serum halflife values were used in formulating a revised kanamycin dosage and frequency of administration schedule.
AB - This study documents an important change in the kanamycin susceptibilities of Escherichia coli strains cultivated from neonates. Whereas some nurseries have in the past experienced resistance rates as high as 70%, recent surveillance of seven North American nurseries demonstrated that 90% or more of E. coli strains are currently susceptible to kanamycin. Pharmacokinetic studies of 65 babies treated with either 7.5 or 10 mg/kg kanamycin doses revealed that peak serum values varied with dosage, birthweight, and chronologic age. Peak serum levels were below the desired therapeutic range in many babies treated with 7.5 mg/kg doses of kanamycin every 12 hours. Concentrations in cerebrospinal fluid specimens from 21 infants were 0.5 to 12 μg/ml after 7.5 mg/kg kanamycin doses. Calculated distribution volumes, plasma clearances, and serum halflife values were used in formulating a revised kanamycin dosage and frequency of administration schedule.
UR - http://www.scopus.com/inward/record.url?scp=0016806047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016806047&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(75)80234-4
DO - 10.1016/S0022-3476(75)80234-4
M3 - Article
C2 - 1092827
AN - SCOPUS:0016806047
SN - 0022-3476
VL - 86
SP - 949
EP - 956
JO - The Journal of pediatrics
JF - The Journal of pediatrics
IS - 6
ER -